Particella
Private Company
Funding information not available
Overview
Particella is pioneering the development of oral mRNA medicines using a proprietary lipid nanoparticle technology aimed at the intestinal epithelium. Founded in 2021, the company is in the preclinical stage, seeking to overcome the significant challenge of orally delivering nucleic acids, which are typically degraded in the gut. Its platform promises repeatable dosing, a non-immunogenic profile, and a patient-friendly administration route compared to injectable alternatives. If successful, this technology could unlock a new class of treatments for a wide range of gastrointestinal disorders and potentially enable systemic delivery via the gut.
Technology Platform
Proprietary oral lipid nanoparticle (LNP) formulation designed to deliver nucleic acids (e.g., mRNA) to the intestinal epithelium, enabling repeatable, non-immunogenic, oral dosing.
Opportunities
Risk Factors
Competitive Landscape
Competition includes other biotechs developing oral delivery platforms (e.g., Rani Therapeutics, Entera Bio) and large pharma investing in alternative technologies. The space for oral nucleic acid delivery is particularly nascent but crowded with academic and startup efforts. Particella's differentiation lies in its specific focus on LNPs for intestinal epithelium delivery.